PEPG arrives at its May 18 clinical update in an unusual position: the stock has dropped 13% over the past week to $1.68, yet short sellers are retreating and Wedbush remains bullish even as it slashes its target for the second time in six weeks.
The week's clearest story is the gap between the price action and what short sellers are actually doing. Short interest has fallen sharply — down nearly 5% on the week to 8.9% of the free float, after peaking above 10% in early April. The direction of travel is unambiguous: shorts have been covering steadily since late March, pulling the position from roughly 10.8% of float down to current levels. That steady retreat suggests the bear thesis has been softening even as the stock itself has drifted lower. Borrowing costs remain low at around 1.1%, well below the mid-April high of 2.5%, and lending availability is loose — reflecting no meaningful friction for new shorts who might want to re-enter.
Options positioning is decidedly one-sided toward calls. The put/call ratio of 0.12 is more than a standard deviation below its 20-day average of 0.17, and the ratio has sat near this low level for most of the past two weeks. The 52-week low is 0.02, so this is not an extreme reading, but the consistent lean toward calls — even through this week's price decline — points to a market that is not positioning for an immediate washout. The ORTEX short score is running at 54, down from 60 earlier in the week, which reflects the partial easing of short pressure.
Analyst sentiment is the most interesting tension in the note. Wedbush cut its price target this morning to $4 from $5, the second reduction since late March and the third in roughly six months — each cut tracking the stock lower. The firm has kept an Outperform rating throughout all three moves, a pattern that signals continuing conviction on the science paired with diminishing confidence on valuation. The mean analyst target now sits at just over $10, which against a $1.68 stock implies enormous optionality priced into the Street's bullish base case — and makes that aggregate figure unreliable as a near-term reference point, likely reflecting older estimates that have not been refreshed. What is current: Wedbush at $4, a 138% premium to where the stock trades. The law firm investor alert filed May 7 adds a separate overhang worth watching, though its implications are early-stage.
The ownership structure offers some important context on who is holding through the decline. RA Capital Management holds 29% of shares, a position it last added to in September 2025 at $3.20 — more than double the current price. Commodore Capital appears to have entered the register in early March, filing a fresh 5.1% stake. Together with the Vanguard and Point72 positions, the top ten holders account for well over half the float, leaving relatively thin free-float supply and helping explain why the short position — despite being nearly 9% of float — has not pushed the cost to borrow materially higher.
The next event is the one that matters most. Q1 results released after the close on May 12 showed EPS of -$0.26, beating the -$0.31 consensus estimate. But the scheduled May 18 readout is the real binary. The prior two earnings reactions ran -14% and -2.8% on the day, with a -14% and -13% five-day follow-through respectively — a consistent pattern of post-event selling even when results were mixed rather than outright negative. The 10mg/kg cohort data from the FREEDOM-2 study, which management has framed as a go/no-go decision point for PGN-EDODM1, determines whether the bull case retains any clinical foundation at current price levels. With shorts covering, calls dominant, and a concentrated ownership base holding firm, the setup into May 18 is less about positioning pressure and more about whether the data can finally break the pattern of post-event declines.
See the live data behind this article on ORTEX.
Open PEPG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
